Silexion Therapeutics Advances Cancer Treatment with Promising RNAi Therapy Results
Silexion Therapeutics reports significant preclinical success with its RNAi cancer therapy SIL-204, demonstrating potential breakthrough treatment for KRAS-driven cancers amid increasing industry investment in precision oncology.
Read the full story
























